Analysis of survival time and benefits of postoperative radiotherapy in resected small cell lung cancer patients
10.3760/cma.j.cn113030-20220421-00147
- VernacularTitle:手术治疗小细胞肺癌患者生存时间及术后放疗价值分析
- Author:
Yanyang WANG
1
;
Xiaolong DING
;
Xuehong BAI
;
Liang YU
;
Jinxi HE
;
Ren ZHAO
Author Information
1. 宁夏医科大学总医院肿瘤医院放疗科，银川 750004
- Keywords:
Small cell lung carcinoma;
Surgical treatment;
Prognostic factors;
TNM staging;
Postoperative adjuvant radiotherapy
- From:
Chinese Journal of Radiation Oncology
2023;32(3):201-206
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the survival time, prognostic factors and the value of postoperative thoracic radiotherapy in resected small cell lung cancer (SCLC) patients.Methods:Clinic opathological data of SCLC patients who received surgical treatment in Cancer Hospital & General Hospital of Ningxia Medical University from April 2014 to September 2021 were enrolled in this retrospective study. All patients were subject to follow-up. The survival time of SCLC patients was evaluated by Kaplan-Meier method. Univariate and multivariate analyses of prognostic factors were performed by Cox proportional hazard model.Results:A total of 64 patients with SCLC were enrolled in the study. The 5-year overall survival (OS) rate was 43.5%. Univariate analysis showed that TNM staging ( P=0.027), postoperative neutrophil-lymphocyte ratio (NLR) ( P=0.039) and adjuvant thoracic radiotherapy ( P=0.041) were the prognostic factors. Multivariate analysis showed that TNM staging ( P=0.038) and adjuvant thoracic radiotherapy ( P=0.022) were the prognostic factors in patients with SCLC. The 5-year OS rates of patients with and without adjuvant thoracic radiotherapy were 71.6% and 35.4% ( P=0.028), respectively. There was a statistically significant difference in the 5-year OS rates between pathological stage N 2 SCLC patients with or without adjuvant thoracic radiotherapy (75.0% vs. 0%, P=0.030). Conclusions:TNM staging and postoperative adjuvant thoracic radiotherapy are prognostic factors in patients with SCLC undergoing surgical treatment. Pathological stage N 2 SCLC patients can benefit from adjuvant thoracic radiotherapy.
